[1]张长彪,彭冉东,赵军,等.益肾地黄汤联合利塞膦酸钠治疗肾阳虚型绝经后骨质疏松症45例[J].西部中医药,2017,30(04):1-4.
　ZHANG Changbiao,PENG Randong,ZHAO Jun,et al.YiShen Dihuang Tang Combined with Risedronate Sodium in the Treatment for 45 Cases of Postmenopausal Osteoporosis of Kidney Yang Deficiency Type[J].Western Journal of Traditional Chinese Medicine,2017,30(04):1-4.
点击复制

益肾地黄汤联合利塞膦酸钠治疗肾阳虚型绝经后骨质疏松症45例()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
30
期数:
2017年04期
页码:
1-4
栏目:
出版日期:
2017-04-15

文章信息/Info

Title:
YiShen Dihuang Tang Combined with Risedronate Sodium in the Treatment for 45 Cases of Postmenopausal Osteoporosis of Kidney Yang Deficiency Type
文章编号:
1004-6852(2017)04-0001-04
作者:
张长彪1，彭冉东2，赵军3，邓强3，李中锋3，关新红1，张秀1
1 武威职业学院直属附属医院/凉州区中医医院，甘肃 武威 733000； 2 甘肃中医药大学； 3 甘肃省中医院
Author(s):
ZHANG Changbiao1, PENG Randong2, ZHAO Jun3, DENG Qiang3, LI Zhongfeng3, GUAN Xinhong1, ZHANG Xiu1
1 Wuwei Vocational Celleges Clirectly Affiliated Hospital / TCM Hospital of Lanzhou District,Wuwei 733000, China; 2 Gansu University of Traditional Chinese Medicine; 3 Gansu Provincial Hospital of TCM
关键词:
骨质疏松症; 绝经后; 肾阳虚型; 益肾地黄汤; 利塞膦酸钠
Keywords:
osteoporosis;  postmenopausal;  kidney Yang deficiency type;  YiShen Dihuang Tang;  risedronate sodium
分类号:
R681.5
文献标志码:
A
摘要:
目的：观察益肾地黄汤联合利塞膦酸钠治疗肾阳虚型绝经后骨质疏松症的有效性及安全性。方法：将88例患者随机分为观察组45例、对照组43例，观察组采用益肾地黄汤加利塞膦酸钠片治疗；对照组单纯口服利塞膦酸钠片，疗程均为12个月，观察2组临床疗效、肾阳虚症状积分改善情况，检测治疗前后2组腰椎(L2～4)侧位骨密度值(BMD)及雌二醇(E2)、碱性磷酸酶(ALP)、血清骨钙素(BGP)、尿Ⅰ型胶原交联氨基末端肽与肌酐比值(NTX/Cr)等相关指标变化，并监测肝功能、肾功能、血常规、尿常规、心电图、血压等药物安全性指标，记录不良事件的发生。结果：腰膝酸软、畏寒肢冷、夜尿频多、神疲倦怠及总积分2组治疗后组内及组间比较差异均有统计学意义(P＜0.05)。总有效率观察组为91.1%，对照组为86.0%，2组比较差异无统计学意义(P＞0.05)。BMD值2组治疗后组内及组间比较差异均有统计学意义(P＜0.05)。E2、ALP、BGP、NTX 2组治疗后组内及组间比较差异均有统计学意义(P＜0.05)。不良反应发生率观察组为4.4%，对照组为14.0%，2组比较差异有统计学意义(P＜0.05)。结论：与单纯服用利塞膦酸钠片相比，益肾地黄汤联合利塞膦酸钠片能显著提高绝经后妇女雌激素水平，降低骨转换率，增加骨密度，改善临床症状，减少不良反应，是治疗肾阳虚型绝经后骨质疏松症安全有效的方法。
Abstract:
Objective: To observe the effectiveness and safety of YiShen Dihuang Tang combined with risedronate sodium in the treatment of postmenopausal osteoporosis of kidney Yang deficiency type. Methods: 88 patients were randomly divided into the observation group (45 cases) and the control group (43 cases). The observation group was treated by YiShen Dihuang Tang combined with risedronate sodium tablets; and the control group orally took risedronate sodium tablets. The treatment courses of two groups were 12 months. Clinical effects and the improvement conditions of scores of kidney-yang deficiency symptoms of two groups were observed. Related indexes changes of two groups such as bone mineral density (BMD) of lateral position of lumbar spines (L2～4) ,estradiol(E2) ,alkaline phosphatase (ALP), serum osteocalcin (BGP), the ratio of urinary pyridinoline cross-linked N-telopeptides of Type I collagen (NTX) and creatinine(NTX/Cr) were compared before and after treatment. Liver function, kidney function, routine blood test, routine urine test, electrocardiogram, blood pressure and other drug safety indexes were monitored. The occurrences of the adverse events were recorded. Results: Compared the symptoms of two groups such as soreness and weakness of waist and knees, aversion to cold and cold limbs, frequent urine, bad spirit and fatigue and the total scores of them within and between two groups, the differences were statistically significant(P＜0.05). The total effective rate of the observation group was 91.1%, and that of the control group was 86.5%, and the differences between two groups were not significant(P＞0.05). Compared the BMD value between and within two groups after the treatment, the differences were statistically significant(P＜0.05). Compared E2, ALP, BGP and NTX between and within two groups after the treatment, the differences were statistically significant(P＜0.05). Adverse reactions incidence rate of the observation group was 4.4%, and that of the control group was 14.0%, and the differences between two groups were significant(P＜0.05). Conclusion: Compared with only orally taking risedronate sodium tablets, YiShen Dihuang Tang combined with risedronate sodium can significantly increase estrogen level of postmenopausal women, decrease bone turnover rate, increase bone density, improve clinical symptoms, reduce adverse reactions; and it is an effective and safe method for treating postmenopausal osteoporosis of kidney Yang deficiency type.

相似文献/References:

[1]谢栋,陈大军,马国亮,等.原发性骨质疏松症的骨密度与中医脏腑辨证的相关性研究*[J].西部中医药,2015,28(02):82.
[2]梁敏.绝经后骨质疏松症42例护理体会[J].西部中医药,2015,28(12):129.
[3]张彩凤,程卫东△,王彩霞,等.玫参胶囊治疗围绝经期骨质疏松症60例[J].西部中医药,2012,25(05):16.
　ZHANG Cai-feng,CHENG Wei-dong,WANG Cai-xia,et al.MeiShen Capsule in Treating 60 Cases of Menopausal Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2012,25(04):16.
[4]张德宏,李晶.老年骨质疏松症的病因病机及防治原则探析[J].西部中医药,2013,26(03):90.
　ZHANG Dehong,LI Jing.The Etiology, Pathogenesis and Prevention Principles of Senile Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2013,26(04):90.
[5]李晶,宋敏△,罗晓,等.淫羊藿总黄酮对去势大鼠股骨骨组织形态学及生物力学的影响*[J].西部中医药,2014,27(07):13.
　LI Jing,SONG Min,LUO Xiao,et al.Effects of Total Flavonoids of Epimedium on Biodynamics and Bone Morphological Metrology of Ovariectomized Rats[J].Western Journal of Traditional Chinese Medicine,2014,27(04):13.
[6]李非,李红专,叶丙霖.原发性骨质疏松症的中医药研究现状[J].西部中医药,2016,29(03):136.
　LI Fei,LI Hongzhuan,YE Binlin.Research Status of Primary Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2016,29(04):136.
[7]薄云,夏冰杰,赵丽艳,等.疏肝滋肾汤治疗绝经后女性骨关节炎的临床观察[J].西部中医药,2016,29(07):93.
　BO Yun,XIA Bingjie,ZHAO Liyan,et al.Clinical Observation on ShuGan ZiShen Tang in Osteoarthritis of the Female Patients after the Menopause[J].Western Journal of Traditional Chinese Medicine,2016,29(04):93.
[8]王继宏,杨鹏玲.柴芍抗松汤治疗老年原发性骨质疏松症伴抑郁39例[J].西部中医药,2018,31(10):74.
　WANG Jihong,YANG Pengling.ChaiShao KangSong Decoction in Treating 39 Senile Patients Suffering Primary Osteoporosis Accompanying Depression[J].Western Journal of Traditional Chinese Medicine,2018,31(04):74.
[9]董林,雷宁波,邢涛,等.损伤胶囊对绝经后骨质疏松症患者疼痛、骨密度及骨代谢生化指标的影响[J].西部中医药,2017,30(11):8.
　DONG Lin,LEI Ningbo,XING Tao,et al.The Effects of Damage Capsules on the Pain, Bone Mineral Density and Biochemical Markers of Bone Metabolism of Postmenopausal Osteoporosis Patients[J].Western Journal of Traditional Chinese Medicine,2017,30(04):8.
[10]马风英.仙灵骨葆胶囊联合甲氨蝶呤治疗类风湿性关节炎继发骨质疏松症37例[J].西部中医药,2018,31(02):98.
　MA Fengying.XianLing GuBao Capsules Combined with Methotrexate in Treating 37 Rheumatiod Arthritis Patients with Secondary Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2018,31(04):98.
[11]王想福,陈伟国,叶丙霖,等.从“肝肾同源”理论论治绝经后妇女骨质疏松症的研究进展[J].西部中医药,2019,32(06):155.
　WANG Xiangfu,CHEN Weiguo,YE Binglin,et al.Research Progress of Treatment for Osteoporosis of Postmenopausal Women Based on the Theory of ''Same Source of Liver and Kidney ''[J].Western Journal of Traditional Chinese Medicine,2019,32(04):155.
[12]赵军,邓强,彭冉东,等.综合干预方案调治绝经后骨质疏松症患者血瘀质的临床研究[J].西部中医药,2019,32(07):9.
　ZHAO Jun,DENG Qiang,PENG Randong,et al.Clinical Study on Treating Postmenopausal Osteoporosis of Blood Stagnation Constitution with Comprehensive Intervention Regimen[J].Western Journal of Traditional Chinese Medicine,2019,32(04):9.
[13]熊巍,王贵梅.抗骨质疏松胶囊对绝经后骨质疏松症患者骨密度及骨代谢生化指标的影响[J].西部中医药,2022,35(03):104.[doi:10.12174/j.issn.2096-9600.2022.03.23]
　XIONG Wei,WANG Guimei.Influence of Anti-osteoporosis Capsules on Bone Mineral Density and Bone Metabolism Biochemical Markers in Patients with Postmenopausal Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2022,35(04):104.[doi:10.12174/j.issn.2096-9600.2022.03.23]
[14]赵军,师建平.蒙药蓝刺头对去卵巢骨质疏松大鼠TGF-β1、UI、BMD的作用[J].西部中医药,2022,35(07):16.[doi:10.12174/j.issn.2096-9600.2022.07.04]
　ZHAO Jun,SHI Jianping.Influence of Mongolian Medicine Lancitou on TGF-β1, UI and BMD of Ovariectomized Rats with Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2022,35(04):16.[doi:10.12174/j.issn.2096-9600.2022.07.04]
[15]郭晛,任艳玲.中医药基于骨髓脂肪组织能量代谢防治绝经后骨质疏松症机制探讨[J].西部中医药,2023,36(09):51.[doi:10.12174/j.issn.2096-9600.2023.09.11]
　GUO Xian,REN Yanling.Study on the Mechanism of TCM Intervention on Energy Metabolism of Bone Marrow Adipose Tissue in the Prevention and Treatment of Postmenopausal Osteoporosis[J].Western Journal of Traditional Chinese Medicine,2023,36(04):51.[doi:10.12174/j.issn.2096-9600.2023.09.11]

备注/Memo

备注/Memo:
收稿日期：2016-11-07 *基金项目：国家中医临床研究基地业务建设第二批科研专项课题(编号JDZX2015039)；2016年甘肃省中医药管理局科研立项课题(编号GZK-2016-49)；2015年武威市第二批科技计划项目(编号WW150205)。 作者简介：张长彪(1971—)，男，副主任医师。研究方向：脊柱、关节等相关疾病的中西医结合诊治。
更新日期/Last Update: 2017-04-15